MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$41,135K
Free Cash flow
-$46,504K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from labcorp sale
Borrowings on lines of credit
Accounts payable
Others
Negative Cash Flow Breakdown
Revenue from the receipt of equi...
Gain on sale of assets
Share repurchase
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-8,416
-54,848
-31,257
21,631
Depreciation and amortization
22,408
22,201
22,373
22,740
Non-cash interest
2,550
2,433
2,391
2,309
Amortization of deferred financing costs
138
137
137
138
Losses from investments in investees
0
-2
-17
-3
Equity-based compensation employees and non-employees
2,238
2,735
2,917
2,969
Impairment charges
-
-
0
1,007
Revenue from the receipt of equity
27,269
-
-
-
Realized gain on disposal of fixed assets and sales of equity securities
-149
34
-601
-12
Change in fair value of equity securities and derivative instruments
2,353
-3,934
824
287
Loss on conversion convertible senior notes
-
-
0
-
Inducement expense and loss on debt conversion
0
-
0
0
Change in fair value of contingent consideration
-
-
0
-
Deferred income tax (benefit) provision
-6,265
-7,890
-10,149
18,287
Gain on sale of assets
18,070
-
0
101,576
Accounts receivable, net
2,388
-9,526
-6,709
-4,389
Inventory, net
-2,842
-191
-1,173
-624
Other current assets and prepaid expenses
6,087
-6,969
4,137
-1,035
Other assets
172
126
-121
-412
Accounts payable
5,369
3,496
-17,060
-5,244
Foreign currency measurement
136
126
4,843
-2,676
Accrued expenses and other liabilities
-8,310
-8,162
-3,776
-420
Net cash used in operating activities
-43,500
-19,310
-25,921
-34,647
Investments in investees
0
0
0
7,665
Proceeds from sale of equity securities
0
-51,655
-
0
Purchase of marketable securities
-
-
-
0
Proceeds from sale of investments
-
-
52,182
-
Proceeds from the sale of property, plant and equipment
148
33
93
13
Capital expenditures
3,004
1,833
2,666
3,135
Proceeds from labcorp sales including escrow released
-
-
-
197,770
Proceeds from labcorp sale
18,392
-
197,770
-
Net cash (used in) provided by investing activities
15,536
-1,800
-2,046
194,648
Issuance of 3.00 convertible senior notes, net (including related parties)
-
-
0
0
Issuance of 2044 notes
-
-
0
0
Debt issuance costs
-
-
0
0
Share repurchase
13,020
4,767
13,507
15,278
Proceeds from the exercise of common stock options
-339
0
-133
0
Repurchase of 2029 convertible notes
-
-
0
62,208
Borrowings on lines of credit
10,178
8,486
8,528
7,869
Repayments of lines of credit
9,845
8,876
13,227
8,797
Settlement of convertible notes
0
0
0
-62,208
Net cash used in financing activities
-13,026
-5,157
-18,339
-16,206
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-145
-908
174
-316
Net (decrease) increase in cash, cash equivalents and restricted cash
-41,135
-27,175
-46,132
143,479
Cash, cash equivalents and restricted cash at beginning of period
355,567
382,742
428,874
445,615
Cash, cash equivalents and restricted cash at end of period
314,432
355,567
382,742
428,874
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from labcorp
sale
$18,392K
Proceeds from the sale of
property, plant and...
$148K
(-18.23%↓ Y/Y)
Net cash (used in)
provided by investing...
$15,536K
(-58.78%↓ Y/Y)
Canceled cashflow
$3,004K
Net (decrease)
increase in cash, cash...
-$41,135K
(74.33%↑ Y/Y)
Canceled cashflow
$15,536K
Depreciation and
amortization
$22,408K
(-51.83%↓ Y/Y)
Accounts payable
$5,369K
(-33.61%↓ Y/Y)
Inventory, net
-$2,842K
(-148.05%↓ Y/Y)
Non-cash interest
$2,550K
(-95.86%↓ Y/Y)
Equity-based compensation
employees and...
$2,238K
(-53.65%↓ Y/Y)
Realized gain on disposal
of fixed assets and...
-$149K
(-103.86%↓ Y/Y)
Amortization of deferred
financing costs
$138K
(-97.22%↓ Y/Y)
Foreign currency
measurement
$136K
(106.84%↑ Y/Y)
Borrowings on lines of
credit
$10,178K
(-38.82%↓ Y/Y)
Capital expenditures
$3,004K
(-53.62%↓ Y/Y)
Net cash used in
operating activities
-$43,500K
(63.13%↑ Y/Y)
Canceled cashflow
$35,830K
Net cash used in
financing activities
-$13,026K
(84.40%↑ Y/Y)
Effect of exchange rate
changes on cash, cash...
-$145K
(-104.06%↓ Y/Y)
Canceled cashflow
$10,178K
Revenue from the receipt
of equity
$27,269K
Gain on sale of assets
$18,070K
Net loss
-$8,416K
(96.10%↑ Y/Y)
Accrued expenses and
other liabilities
-$8,310K
(80.96%↑ Y/Y)
Deferred income tax
(benefit) provision
-$6,265K
(72.92%↑ Y/Y)
Other current assets
and prepaid...
$6,087K
(162.60%↑ Y/Y)
Accounts receivable, net
$2,388K
(112.49%↑ Y/Y)
Change in fair value of
equity securities and...
$2,353K
(235.70%↑ Y/Y)
Other assets
$172K
(-66.27%↓ Y/Y)
Share repurchase
$13,020K
(-28.68%↓ Y/Y)
Repayments of lines of
credit
$9,845K
(-49.22%↓ Y/Y)
Proceeds from the
exercise of common stock...
-$339K
(-175.61%↓ Y/Y)
Buy us a coffee
OPKO HEALTH, INC. (OPK)
OPKO HEALTH, INC. (OPK)